TAVI or valve surgery · Decision guide

TAVI vs surgical aortic valve replacement: suitability, risks and lifetime planning

Name: TAVI vs surgical aortic valve replacement: suitability, risks and lifetime planning
Creator: Yevhenii Kozlov

Compare the treatment that fits the valve and the person, including what might be needed years later.

Research by Yevhenii Kozlov · Co-Founder of BookimedUpdated 8 October 2026Sources linked throughout

At a glance

TAVI and surgical replacement can both treat severe aortic stenosis. TAVI introduces a tissue valve by catheter; surgery removes the diseased valve and can also treat associated coronary or aortic disease.

2–3 days versus about 1 week

Typical NHS hospital guidance for TAVI and surgical replacement respectively; individual recovery varies.

Sources: NHS: valve recovery

1,000 randomized patients · 7 years

PARTNER 3 found no significant difference in its primary composite outcomes between transfemoral TAVR and surgery in low-risk patients.

Sources: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years

Different risk patterns

TAVI more often involves vascular complications, paravalvular leak and new pacemakers; surgery more often involves severe bleeding, kidney injury and new AF in guideline evidence.

Sources: 2025 ESC/EACTS Guidelines for the management of valvular heart disease

Find a heart valve specialist

Free Bookimed support. Compare options before deciding.

Benefits and trade-offs

Potential advantages

TAVI usually reduces the initial hospital and recovery burden; surgery can provide a mechanical valve or combine valve replacement with other cardiac work.
Sources: NHS: valve types · NHS: valve recovery · ESC/EACTS valve guidance (2025)

Trade-offs and limits

Seven-year trial results do not establish equal lifetime durability in young patients or all devices and anatomies. Future valve and coronary access can constrain the choice.
Sources: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years · 2025 ESC/EACTS Guidelines for the management of valvular heart disease

First establish whether replacement is indicated

This comparison concerns aortic stenosis: narrowing of the aortic valve. A recommendation must first establish the severity of the disease and the reason to intervene now, considering symptoms, heart function and relevant test findings.

Aortic regurgitation, active valve infection and failure of a previously implanted valve need their own assessment. Evidence from trials of native aortic stenosis should not be applied to those problems without qualification.

Sources: 2020 ACC/AHA Heart Valve Disease Guideline: Key Perspectives, Part 1 · 2025 ESC/EACTS Guidelines for the management of valvular heart disease: introduction

Aortic valve disease Valve infection Repeat surgery

What differs between TAVI and surgery?

Feature	TAVI / TAVR	Surgical replacement
Access	Catheter, usually via a suitable groin artery	Sternotomy or selected smaller chest incision
Old valve	New valve expands within it	Diseased valve is removed
Replacement	Biological tissue valve	Tissue or mechanical valve
Heart support	Routine TAVI does not require stopping the heart	Heart-lung support is used
Associated disease	Other conditions may need a separate procedure	Bypass, aortic repair or another valve procedure may be combined

Sources: NHS: valve types · Transcatheter aortic valve replacement (TAVR) · Update on TAVI Indications From 2020 ACC/AHA Valvular Guidelines

Open-heart surgery Heart valves

What do the guidelines say about age?

The 2025 ESC/EACTS guideline recommends TAVI from age 70 for a three-leaflet (tricuspid) aortic valve when anatomy is suitable and access through the groin artery is feasible, and surgery below 70 when surgical risk is low. Other candidates need an individualized Heart Team choice. Here “tricuspid” describes the aortic valve’s three leaflets, not the separate tricuspid valve.

Guidelines do not use identical age bands. The 2020 ACC/AHA recommendations favour surgery below 65 or with life expectancy over 20 years; favour transfemoral TAVI above 80 or with life expectancy below 10 years when feasible; and use shared decision-making from 65 to 80 in symptomatic patients suitable for either. These dated frameworks are not automatic eligibility rules.

Sources: 2025 ESC/EACTS Guidelines for the management of valvular heart disease · 2025 ESC/EACTS Guidelines for the management of valvular heart disease: official release · 2020 ACC/AHA Heart Valve Disease Guideline: Key Perspectives, Part 1

Which findings can change the recommendation?

Echocardiography, CT and coronary assessment establish these anatomical findings. Age and a surgical-risk score add context, but neither defines the entire treatment choice.

Finding that changes the choice	Why it matters
Bicuspid aortic valve	Surgery remains the main option, especially in younger patients or with aortic disease. Selected patients at increased surgical risk may be considered for TAVI if anatomy is suitable.
Difficult artery access or valve/root anatomy	Surgery is generally preferred when the transfemoral route is unsuitable. Other TAVI access routes may be considered when surgery is unsuitable.
Aorta disease, complex coronary disease or another valve problem	Surgery may address more than one problem in a single operation.
Major frailty or serious illness beyond the valve	The team must assess likely survival, symptom relief and quality-of-life benefit from either treatment.
Small valve opening and a long expected lifespan	The size and design chosen now can affect later valve treatment.

Sources: 2025 ESC/EACTS Guidelines for the management of valvular heart disease · 2020 ACC/AHA Heart Valve Disease Guideline: Key Perspectives, Part 1 · Update on TAVI Indications From 2020 ACC/AHA Valvular Guidelines

Find a heart valve specialist Aortic surgery

Which risks should the team compare?

Both approaches have risks, including stroke, bleeding, infection and death. Across the evidence summarized in the 2025 guideline, vascular complications, leakage around the valve and new pacemakers occur more often after TAVI; severe bleeding, acute kidney injury and new atrial fibrillation occur more often after surgery. These patterns do not predict an individual outcome.

Request procedure-specific estimates for someone with similar anatomy and health. A low surgical risk score does not answer every question about TAVI anatomy or future procedures, and a shorter initial stay is not the same outcome as long-term survival.

Sources: Transcatheter aortic valve replacement (TAVR) · 2025 ESC/EACTS Guidelines for the management of valvular heart disease · Heart Surgery: Risks · STS risk calculators · STS rating methodology

Open-heart surgery Compare surgeon expertise

What does seven-year randomized evidence show?

PARTNER 3 randomized 1,000 patients with severe, symptomatic aortic stenosis and low surgical risk to transfemoral TAVR or surgery. At seven years, the estimated combined incidence of death, stroke or relevant rehospitalization was 34.6% after TAVR and 37.2% after surgery; the difference was −2.6 percentage points (95% confidence interval −9.0 to 3.7). The primary comparisons did not show a statistically significant difference.

Bioprosthetic valve failure was reported in 6.9% and 7.5%, respectively. This is useful follow-up for the studied population and valve approach, not proof of equal lifetime durability in younger patients, all anatomies or every device. These combined seven-year events are not procedural death rates. The study was funded by Edwards Lifesciences; the report appeared online in 2025 and in the 2026 journal issue.

Sources: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years

Plan the next intervention before choosing the first

A tissue valve can deteriorate. Another catheter valve inside it may be possible, but it is not a guaranteed future solution. Planning needs to consider space for another valve, the risk of blocking a coronary artery and whether those arteries will remain accessible for future treatment.

A mechanical valve offers a different durability trade-off and requires lifelong anticoagulation. Its suitability depends on the person’s circumstances and preferences; TAVI does not offer a mechanical-valve option.

A tissue valve can deteriorate and require another intervention.
Valve size and coronary anatomy can limit future valve-in-valve treatment.
A future valve can affect access to the coronary arteries.
A mechanical valve offers durability with lifelong anticoagulation; TAVI does not provide this option.

Sources: 2025 ESC/EACTS Guidelines for the management of valvular heart disease · NHS: valve types · Transcatheter aortic valve replacement (TAVR)

Heart valves Repeat surgery

Recovery and follow-up: a shorter stay still needs a plan

NHS guidance describes roughly two to three days in hospital after TAVI versus about a week after surgical valve replacement, with two to three months for full recovery after chest surgery. Actual discharge and recovery vary; these are general patient-information timelines, not a promise for a particular centre.

Both treatments require valve surveillance and medication review after discharge. Early walking, rehabilitation and return travel follow different milestones; a shorter hospital stay does not remove the need for continuing cardiac care.

Sources: NHS: valve recovery · Transcatheter aortic valve replacement (TAVR)

Recovery Find a heart valve specialist Costs & quotes

Specialists for this treatment pathway

Explore each specialist’s clinical focus, current programme and the studies relevant to this treatment. The listed roles include cardiac surgeons and, where appropriate, interventional cardiologists.